MTI consolidation
This article was originally published in The Gray Sheet
Executive Summary
Micro Therapeutics shutters operations in Bochum, Germany Dec. 30 to bring manufacturing and R&D functions to its headquarters in Irvine, Calif. MTI gained the Bochum facility in a $40 mil. purchase of Dendron (1"The Gray Sheet" Sept. 9, 2002, p. 13). MTI will terminate 60 employees, although key R&D personnel likely will move to Irvine...
You may also be interested in...
Micro Therapeutics Fills Out Aneurysm Pipeline With Dendron Embolic Coils
Micro Therapeutics, Inc. expects to obtain 510(k) clearance for Dendron GmbH's line of neurovascular embolic coils for brain aneurysms by mid-2003
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.